Program
Aripiprazole
Also written as “aripiprazole”, “Aripiprazole IM Depot” and “Antidepressant + Aripiprazole”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Tourette Syndrome · Autistic Disorder, led by 10 companies.
Drug pageAripiprazole: every studyMany companies study it; this page follows only the 124 they lead. All 292 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 1120 open or running | phase 4since Mar 26, 2004 | May 7, 2002 | none ahead |
| Johnson & Johnsonits history only | 40 open or running | phase 4since Feb 10, 2012 | Feb 10, 2012 | none ahead |
| Abdi İbrahim Otsukaits history only | 10 open or running | phase 4since Feb 23, 2016 | Feb 23, 2016 | none ahead |
| Chengdu Kanghong Pharmaceutical Groupits history only | 10 open or running | no phasesince Jul 24, 2017 | Jul 24, 2017 | none ahead |
| CMG Pharmaceuticalits history only | 10 open or running | phase 1since Jun 4, 2015 | Jun 4, 2015 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | no phasesince Mar 23, 2026 | Mar 23, 2026 | Sep 5, 2027NCT07547384 |
| Genovate Biotechnologyits history only | 10 open or running | phase 4since Oct 8, 2007 | Oct 8, 2007 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Mar 27, 2023 | Mar 27, 2023 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Aug 18, 2011 | Aug 18, 2011 | none ahead |
| H. Lundbeckits history only | 10 open or running | phase 3since Oct 7, 2013 | Oct 7, 2013 | none ahead |
Also a collaborator on its studies: PRA Health Sciences, Covance and Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Apr 2, 2009.
- May 2, 20172 phase 1 studies in SchizophreniaOtsuka · NCT03150771, NCT03287505
- May 11, 2017Phase 3 study in SchizophreniaOtsuka · NCT03172871 · 436 enrolled · China
- Jul 24, 2017Chengdu Kanghong Pharmaceutical Group’s first study: no phase study in BioequivalenceNew to Chengdu Kanghong Pharmaceutical GroupChengdu Kanghong Pharmaceutical Group · NCT03232710 · 66 enrolled · China
- Sep 11, 2017Phase 1 study in SchizophreniaOtsuka · NCT03285503 · 12 enrolled · China
- Dec 13, 2017Phase 4 study in SchizophreniaOtsuka · NCT03376763 · 201 enrolled · Korea, Republic of
- Mar 27, 20182 phase 3 studiesOtsuka · NCT03487783, NCT03487770
- May 25, 2018Phase 4 study in SchizophreniaOtsuka · NCT03568500 · 44 enrolled · United Kingdom
- Sep 5, 2018Phase 4 study in Tourette SyndromeOtsuka · NCT03661983 · 36 enrolled · United States, Canada, Hungary
- Feb 12, 2019Phase 1 study in SchizophreniaOtsuka · NCT03854409 · 72 enrolled · United States
- Mar 21, 2019Phase 3 study in SchizophreniaOtsuka · NCT03892889 · 277 enrolled · United States
- Jul 19, 2019Phase 2 study in SchizophreniaOtsuka · NCT04030143 · 266 enrolled · United States
- Mar 27, 2023Genuine Research Center, Egypt’s first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05804721 · 29 enrolled · Egypt
- Mar 29, 2024No phase study in Mental DisordersOtsuka · NCT06372210 · 54 enrolled · United States
- Mar 23, 2026CSPC Pharmaceutical Group’s first study: no phase study in SchizophreniaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07547384 · 116 planned
Ahead
- Sep 5, 2027Primary completion: no phase study in SchizophreniaCSPC Pharmaceutical Group · NCT07547384
TargetBeta
“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brexpiprazolerule | Otsuka | phase 4 | 70 |
Studies
The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07547384Schizophrenia | – | Not yet recruiting | CSPC Pharmaceutical Group | Sep 5, 2027 | 116 |
| NCT06372210Mental Disorders · United States | – | Completed | Otsuka | Jul 19, 2023 | 54 |
| NCT05804721Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Nov 7, 2022 | 29 |
| NCT04030143Schizophrenia · United States | 2 | Completed | Otsuka | Jul 8, 2020 | 266 |
| NCT03892889Schizophrenia · United States | 3 | Terminated | Otsuka | Aug 12, 2020 | 277 |
| NCT03854409Schizophrenia · United States | 1 | Completed | Otsuka | Apr 5, 2019 | 72 |
| NCT03661983Tourette Syndrome · United States, Canada, Hungary | 4 | Terminated | Otsuka | Jun 30, 2020 | 36 |
| NCT03568500Schizophrenia · United Kingdom | 4 | Completed | Otsuka | May 21, 2019 | 44 |
| NCT03487783Tourette Syndrome · China | 3 | Completed | Otsuka | Feb 14, 2020 | 121 |
| NCT03487770Autistic Disorder · China | 3 | Completed | Otsuka | Apr 21, 2020 | 111 |
| NCT03376763Schizophrenia · Korea, Republic of | 4 | Completed | Otsuka | Nov 19, 2021 | 201 |
| NCT03285503Schizophrenia · China | 1 | Completed | Otsuka | Oct 14, 2019 | 12 |
| NCT03232710Bioequivalence · China | – | UNKNOWN | Chengdu Kanghong Pharmaceutical Group | Apr 30, 2018 | 66 |
| NCT03287505Schizophrenia · China | 1 | Completed | Otsuka | Nov 8, 2019 | 24 |
| NCT03172871Schizophrenia · China | 3 | Completed | Otsuka | Jul 22, 2019 | 436 |
| NCT03150771Schizophrenia · United States | 1 | Completed | Otsuka | Apr 18, 2018 | 36 |
| NCT02722967Schizophrenia · United States | 2 | Completed | Otsuka | Sep 2016 | 49 |
| NCT02697045Schizophrenia · Turkey | 4 | Completed | Abdi İbrahim Otsuka | Mar 31, 2018 | 23 |
| NCT02634463Immunoassay · Belgium | 1 | Completed | Johnson & Johnson | Nov 9, 2016 | 81 |
| NCT02501109Schizophrenia | 1 | Completed | CMG Pharmaceutical | Feb 2016 | 36 |
| NCT02462473Schizophrenia · United States | 2 | Terminated | Johnson & Johnson | Jan 2016 | 9 |
| NCT02435836Schizophrenia | 3 | Terminated | Otsuka | Dec 2012 | 631 |
| NCT02220712Schizophrenia · Japan | 1 | Completed | Otsuka | Apr 2015 | 17 |
| NCT02091882Device Latency · United States | 4 | Completed | Otsuka | Apr 18, 2014 | 30 |
| NCT02054702Schizophrenia | 3 | Completed | Otsuka | Jun 2014 | 97 |
| NCT01981811Schizophrenia · United States | 2 | Withdrawn | Otsuka | May 2014 | 0 |
| NCT01959035Schizophrenia · United States | 3 | Completed | H. Lundbeck | Mar 2015 | 88 |
| NCT01942161Schizophrenia · Japan | 3 | Completed | Otsuka | Nov 2014 | 106 |
| NCT01942148Schizophrenia · Japan | 3 | Completed | Otsuka | Nov 2015 | 68 |
| NCT01909466Schizophrenia · United States | 1 | Completed | Otsuka | Mar 2014 | 141 |
| NCT01870999Schizophrenia · United States | 1 | Completed | Otsuka | Oct 2008 | 41 |
| NCT01727713Tourette Syndrome · United States, Canada, Hungary and more | 3 | Completed | Otsuka | Aug 2014 | 110 |
| NCT01727700Tourette Syndrome · United States, Canada, Germany and more | 3 | Completed | Otsuka | Aug 2013 | 133 |
| NCT01710709Bipolar I · United States, Canada, France and more | 3 | Completed | Otsuka | Nov 2016 | 748 |
| NCT01683058Schizophrenia · United States, Croatia, Latvia | 3 | Completed | Otsuka | Feb 2014 | 74 |
| NCT01663532Schizophrenia · United States, Croatia, Latvia | 3 | Completed | Otsuka | Aug 2013 | 340 |
| NCT01646827Schizophrenia · United States | 1 | Completed | Otsuka | Apr 2013 | 37 |
| NCT01617460Autistic Disorder · Japan | 3 | Completed | Otsuka | Oct 2016 | 86 |
| NCT01617447Autistic Disorder · Japan | 3 | Completed | Otsuka | Jun 2015 | 92 |
| NCT01607762Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2012 | 31 |
| NCT01552772Schizophrenia · United States | 1 | Completed | Otsuka | Apr 2012 | 60 |
| NCT01592201Schizophrenia · Korea, Republic of | 4 | Terminated | Johnson & Johnson | Jun 2013 | 13 |
| NCT01509053Schizophrenia · Belgium, Bulgaria, Canada | 3 | Terminated | Otsuka | Oct 2012 | 30 |
| NCT01432444Schizophrenia · United States, Canada | 3 | Completed | Otsuka | Dec 2013 | 493 |
| NCT01438060Alzheimer Disease | 3 | Completed | Otsuka | Jul 2010 | 232 |
| NCT01429831Depressive Disorder, Major · Taiwan | 4 | Completed | Otsuka | May 2013 | 300 |
| NCT01424449Depressive Disorder · United Kingdom | 1 | Completed | GlaxoSmithKline | Jul 2010 | 7 |
| NCT01418352Tourette Syndrome · United States, Bulgaria, Germany and more | 3 | Completed | Otsuka | Mar 12, 2014 | 83 |
| NCT01418339Tourette Syndrome · United States, Canada, Hungary and more | 3 | Completed | Otsuka | Nov 6, 2013 | 135 |
| NCT01416441Tourette Syndrome · United States, Bulgaria, Canada and more | 3 | Completed | Otsuka | Mar 13, 2014 | 170 |
| NCT01227668Irritability Associated With Autistic Disorder · United States | 4 | Completed | Otsuka | Jun 20, 2012 | 215 |
| NCT01149655Schizophrenia · United States, India, Malaysia and more | 3 | Completed | Otsuka | Nov 2013 | 252 |
| NCT01129882Schizophrenia · United States, Argentina, Australia and more | 3 | Completed | Otsuka | Dec 6, 2018 | 709 |
| NCT01123707Depressive Disorder, Major | 3 | Terminated | Otsuka | Sep 27, 2011 | 173 |
| NCT01122927Mania · United States, Bulgaria, Croatia and more | 3 | Terminated | Otsuka | Aug 2014 | 524 |
| NCT01111565Depressive Disorder, Major · United States, Canada, Croatia and more | 3 | Terminated | Otsuka | Sep 1, 2011 | 137 |
| NCT01111552Depressive Disorder, Major · United States, Australia, Bulgaria and more | 3 | Terminated | Otsuka | Sep 27, 2011 | 237 |
| NCT01111539Depressive Disorder, Major · United States, Estonia, Finland and more | 3 | Terminated | Otsuka | Sep 20, 2011 | 211 |
| NCT01001702Schizophrenia · Argentina, Croatia, India and more | 3 | Completed | Otsuka | Jul 2012 | 85 |
| NCT00882362Depressive Disorder, Major · Japan | 3 | Completed | Otsuka | Jul 2012 | 155 |
How it is read
Names in the registry
- “Aripiprazole”, 81 entries
- “aripiprazole”, 13 entries
- “Aripiprazole IM Depot”, 7 entries
- “Antidepressant + Aripiprazole”, 2 entries
- “Aripiprazole for Injection”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 63 studies
- Bipolar Disorder, 15 studies
- Depressive Disorder, Major, 10 studies
- Tourette Syndrome, 8 studies
- Autistic Disorder, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.